Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ofloxacin
Drug ID BADD_D01598
Description A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Indications and Usage For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.
Marketing Status approved
ATC Code J01MA01; S01AE01; S02AA16
DrugBank ID DB01165
KEGG ID D00453
MeSH ID D015242
PubChem ID 4583
TTD Drug ID D03NHW
NDC Product Code 13985-602; 17478-713; 24208-410; 60505-0560; 63187-472; 63187-734; 0404-7189; 68071-2265; 68788-8195; 70756-607; 75834-119; 11980-779; 53002-1604; 53002-2604; 50090-5186; 60505-0363; 70518-2037; 71209-099; 70518-0192; 70518-3573; 59116-1820; 68788-8178; 70518-3710; 71205-420; 53069-0440; 53002-1324; 63187-184; 64980-432; 71209-097; 58032-0090; 24208-434; 68071-2254; 68071-2544; 68071-2834; 75834-112; 75834-120; 68071-3448; 68788-7693; 72189-108; 50090-1346; 63187-662; 64980-515; 63187-268; 63629-8716; 68788-8264; 68788-8449; 71209-098; 59390-140
UNII A4P49JAZ9H
Synonyms Ofloxacin | Ofloxacine | Tarivid | ORF-28489 | ORF 28489 | ORF28489 | DR-3355 | DR 3355 | DR3355 | Hoe-280 | Hoe 280 | Hoe280 | Ofloxacin Hydrochloride | Ru-43280 | Ru 43280 | Ru43280 | DL-8280 | DL 8280 | DL8280
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 82419-36-1
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mouth ulceration07.05.06.0040.000083%Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.0010.000250%
Myasthenia gravis17.05.04.001; 15.05.08.001; 10.04.05.001--
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nausea07.01.07.001--
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003--Not Available
Neuropathy peripheral17.09.03.0030.000083%Not Available
Neutropenia01.02.03.004--Not Available
Neutrophilia01.02.01.005--Not Available
Nightmare19.02.03.003--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Ocular hyperaemia06.04.05.0040.000283%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.0110.000083%
Oropharyngeal swelling23.04.01.013; 22.04.05.005; 10.01.05.014; 07.05.04.002--Not Available
Otitis externa11.01.05.003; 04.01.02.001--
Otitis media04.05.01.001; 11.01.05.004--
Overdose12.11.01.002--Not Available
Pain08.01.08.0040.000458%
Pain in extremity15.03.04.0100.000292%
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.000167%Not Available
Palpitations02.11.04.0120.000167%
Pancreatitis07.18.01.0010.000083%
Pancreatitis acute07.18.01.0020.000083%Not Available
Pancytopenia01.03.03.0030.000083%Not Available
Paraesthesia23.03.03.094; 17.02.06.0050.000167%
Paranoia19.05.01.005--Not Available
Pathogen resistance11.01.08.049--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene